Trial Profile
A Multiple Treatment Session, Open Label Phase 2 Clinical Study of GSK2398852 Administered Following and Together With GSK2315698 in Cohorts of Patients With Cardiac Amyloidosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Dezamizumab (Primary) ; Miridesap (Primary) ; Miridesap (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 29 Mar 2019 Status changed from suspended to discontinued.
- 22 Aug 2018 Planned End Date changed from 3 Mar 2022 to 23 Sep 2021.
- 22 Aug 2018 Planned primary completion date changed from 3 Mar 2022 to 23 Sep 2021.